Celyad Oncology

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Regulatory News:

Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces that 6,500,000 shares of CFIP CLYD (UK) Limited benefit from a double voting right as of December 8, 2023. As a result, the Company’s total number of voting rights is now 50,296,947.

This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.

Figures – Modified on December 8, 2023, following the Double Voting Right:

Total amount of share capital (EUR)	88,378,224.25
Total Number of shares with single voting rights	32,560,197
Total Number of shares with double voting rights	8,868,375
Total Number of Shares	41,428,572
Total of voting rights	50,296,947
Total number of attributed warrants	3,038,871
Total number of shares with voting rights that could be created following the exercise of the attributed warrants	3,038,871
Total number of diluted shares (Outstanding shares + Warrants)	44,457,443
Total number of diluted voting rights	53,335,818

Contact person for regulated information (financial, transparency)

By law, any transparency declaration must be sent to our Company by email to the attention of Michel Lussier, Chief Executive Officer ad interim (CEO ad interim): [e-mail].

Further questions about the content of this release can be sent to [e-mail].

About Celyad Oncology

Celyad Oncology is a cutting-edge biotechnology company dedicated to pioneering the discovery and advancement of revolutionary technologies for chimeric antigen receptor (CAR) T-cells. Its primary objective is to unlock the potential of its proprietary technology platforms and intellectual property, enabling to be at the forefront of developing next-generation CAR T-cell therapies. By fully leveraging its innovative technology platforms, Celyad Oncology aims to maximize the transformative impact of its candidate CAR T-cell therapies and redefine the future of CAR T-cell treatments. Celyad Oncology is based in Mont-Saint-Guibert, Belgium. For more information, please visit www.celyad.com.